Sepsis-induced cholestasis
โ Scribed by Kurt Lenz; Christine Kapral; Fritz Firlinger; Fritz Wewalka
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 45 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
Hepatic dysfunction and jaundice is a common finding in patients with septic shock. In their excellent review, Dr. Nisha Chand and Prof. Arun J. Sanyal draw attention to an early and suitable management of the underlying infection as the only effective management known yet to improve hepatic dysfunction and jaundice. 1 Maintenance of normoglycemia (blood glucose level between 4.4-6.1 mmol/l) with intensive insulin therapy versus conventional insulin treatment (blood glucose level between 10.0-11.1 mmol/l) was recently shown to reduce mortality in critically ill patients. 2 In a subgroup of 36 patients included in this study, liver biopsies were available. In patients with intensive insulin treatment, ultrastructural and functional abnormalities of hepatic mitochondria could be prevented or reversed. 3 Therefore, strict glycemic control with normoglycemia may be an additional effective procedure to prevent and/or reduce hepatic dysfunction in patients with severe sepsis and septic shock.
๐ SIMILAR VOLUMES
Cholestasis of sepsis is a form of hepatocellular cholestasis that occurs as a result of sepsis. Usually, prior to the development of cholestasis, the manifestations of sepsis dominate the clinical picture. The occurrence of cholestasis is without direct bacterial involvement of the biliary system a
Recent progress in understanding the molecular mechanisms of bile formation and cholestasis have led to new insights into the pathogenesis of drug-induced cholestasis. This review summarizes their variable clinical presentations, examines the role of transport proteins in hepatic drug clearance and
Intrahepatic cholestasis may arise from many sources, and it therefore presents a particular challenge when it develops in the seriously ill patient. A 54-year-old patient with a myeloproliferative disorder is presented, who developed jaundice in the setting of a severe decubital infection, polyphar